New therapies for treating Down syndrome require quality of life measurement

@article{Goodman2013NewTF,
  title={New therapies for treating Down syndrome require quality of life measurement},
  author={M. Goodman and D. Brixner},
  journal={American Journal of Medical Genetics Part A},
  year={2013},
  volume={161}
}
  • M. Goodman, D. Brixner
  • Published 2013
  • Medicine
  • American Journal of Medical Genetics Part A
  • Down syndrome (DS) is the most common genetic cause of cognitive deficits. Using mouse models and therapies for Alzheimer disease, researchers are exploring therapies that may improve cognitive function in people with DS. These developments shift the health economic paradigm of understanding DS from determining the appropriate screening tool to the effect of therapy on quality of life in those with DS. To date, there are no validated quality of life instruments for DS. Research should begin to… CONTINUE READING
    7 Citations

    Topics from this paper

    Down Syndrome and Quality of Life: A Case Report
    • 1
    • PDF
    Cost-effectiveness analysis for triple markers serum screening for Down's syndrome in Thai setting
    • 2
    Quality of health care according to people with Down syndrome, their parents and support staff—A qualitative exploration
    • 4
    • Highly Influenced
    • PDF
    Gajra Raja Medical College, Madhya Pradesh, India
    • A. Alcaraz, Ziad Jamil Al-Sabe, +18 authors Yaneth Mora Márquez
    • 2015

    References

    SHOWING 1-10 OF 37 REFERENCES
    Down syndrome and Alzheimer disease: response to donepezil.
    • 87
    • PDF
    Donepezil Significantly Improves Abilities in Daily Lives of Female down Syndrome Patients with Severe Cognitive Impairment: A 24-Week Randomized, Double-Blind, Placebo-Controlled Trial
    • 42
    Donepezil for the treatment of language deficits in adults with Down syndrome: A preliminary 24‐week open trial
    • 50
    Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study.
    • 37
    Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome
    • 439
    Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10–17
    • 59
    Effects of donepezil on cognitive functioning in Down syndrome.
    • 48
    Dramatic Improvement in down Syndrome—Associated Cognitive Impairment with Donepezil
    • 16
    Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: A clinical report series
    • 40